Translational Multi-Disciplinary Approach for the Drug and Gene Delivery Systems for Cancer Treatment

Area of Science:

• Nanomedicine
• Cancer Therapy
• Drug Delivery Systems

Background:

• Nanoparticulate systems are advanced tools for drug and gene delivery in cancer therapy.
• Despite promising in vitro and in vivo results, clinical translation of nanomedicine remains challenging.
• Existing gaps in translation are linked to oversimplified models, poor correlation of animal data with human outcomes, and complex systemic delivery.

Purpose of the Study:

• To review advancements in nanomedicine for anti-cancer therapy.
• To identify and discuss challenges hindering the clinical translation of nanomedicine.
• To highlight the importance of addressing these challenges for effective nanomedicine implementation.

Main Methods:

• Review of current nanomedicine approaches for cancer therapy.
• Analysis of passive targeting, active targeting, and stimuli-controlled delivery strategies.
• Identification of translational challenges in preclinical testing, regulatory processes, and manufacturing.

Main Results:

• Nanomedicine offers diverse strategies including passive, active, and stimuli-responsive targeting for cancer treatment.
• Significant barriers to clinical translation persist, including inadequate preclinical models and regulatory hurdles.
• Manufacturing scale-up presents difficulties for nanodrug delivery systems.

Conclusions:

• Addressing the identified challenges is crucial for bridging the gap between nanomedicine research and clinical application.
• Improved preclinical models, clear regulatory pathways, and scalable manufacturing are essential for successful nanomedicine translation.
• A comprehensive understanding of these translational issues will facilitate the effective use of nanomedicine in cancer therapy.